{"id":"W3029640994","doi":"10.1200/jco.2020.38.15_suppl.3030","title":"Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Medicine; Lymphoma; Immune system; Refractory (planetary science); Antibody; Cancer; Immune checkpoint; Internal medicine; Cancer research; Oncology; Pharmacology; Immunology; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001170768,0.0001465897,0.0009156907,0.0001124086,0.00007585064,0.00000434555,0.000283805,0.0003389908,0.00011825],"category_scores_gemma":[0.002512327,0.00008613384,0.0001447837,0.000308136,0.0002449638,0.0002409634,0.0000786618,0.0006509094,0.000005951161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001531474,"about_ca_system_score_gemma":0.0006218312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002261335,"about_ca_topic_score_gemma":0.0002508806,"domain_scores_codex":[0.9960269,0.001048263,0.002379602,0.000213147,0.0001484972,0.0001836264],"domain_scores_gemma":[0.9958668,0.001197395,0.002423863,0.0001842061,0.0002713157,0.00005638523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02048863,0.01744666,0.908738,0.00001899498,0.0002827395,0.00001902486,0.001882605,0.0007174156,0.004155932,0.00003968009,0.0008138456,0.04539644],"study_design_scores_gemma":[0.05767741,0.02216148,0.9130584,0.00009411074,0.0000751244,0.00000446275,0.0002508034,0.00004840974,0.0003729927,0.00004020086,0.006122574,0.00009404491],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974225,0.0001383183,0.000008471482,0.001140957,0.0008017689,0.0004148051,0.000003807569,0.000004859162,0.00006456765],"genre_scores_gemma":[0.9993277,0.00002315721,0.0001165166,0.0003846233,0.00007209003,0.000006747206,0.00001274529,0.00001246283,0.00004395833],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04530239,"threshold_uncertainty_score":0.3512436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07030861627519307,"score_gpt":0.3840556391609524,"score_spread":0.3137470228857593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}